{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:41:54Z","timestamp":1783698114192,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hellenic Sepsis Study Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Whether past history of solid stage I\/II inactive cancer has an impact on 28-day mortality of sepsis remains unclear. We aimed to determine the impact of history of stage I or II solid tumor malignancy in complete remission the last 3\u2009years on sepsis outcome.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the database of the Hellenic Sepsis Study Group from 1553 patients with sepsis admitted in the ICU, 83 patients with sepsis by Sepsis-3 definition with past-history of stage I\/II inactive solid malignancy the last 3\u2009years were depicted. A comparator group of 83 patients fully matched for age, severity, type of infection and comorbidities was selected by propensity score matching.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mortality after 28\u2009days was 37.3% in the comparator group and 54.2% in the solid tumor stage I\/II group (odds ratio for death 1.98; p: 0.030). Following step-wise forward Cox regression analysis, septic shock (hazard ratio 1.80), acute renal injury (hazard ratio 2.06), history of coronary heart disease (hazard ratio 0.36) and history of stage I\/II solid tumor malignancy (hazard ratio 1.79) were the only independent variables associated with 28-day mortality. Serum levels of procalcitonin and of soluble urokinase plasminogen activator receptor were similar between the two groups of comparisons.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Past history of stage I\/II solid malignancy is an independent risk factor for unfavorable outcome from sepsis the first 28\u2009days.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4448-7","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T12:02:54Z","timestamp":1570449774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Past history of stage I\/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the Hellenic Sepsis Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dim\u03bfpoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Rovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Patrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Konstantonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Vryza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glykeria","family":"Vlachogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miltiades","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Routsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"4448_CR1","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1097\/00003246-200111000-00014","volume":"29","author":"E Azoulay","year":"2001","unstructured":"Azoulay E, Pochard F, Chevret S, Vinsonneau C, Garrouste M, Cohen Y, et al. Compliance with triage to intensive care recommendations. Crit Care Med. 2001;29:2132\u20136.","journal-title":"Crit Care Med"},{"key":"4448_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00134-008-1320-4","volume":"35","author":"V Peigne","year":"2008","unstructured":"Peigne V, Rusinova K, Karlin L, Darmon M, Fermand JP, Schlemmer B, et al. Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med. 2008;35:512\u20138.","journal-title":"Intensive Care Med"},{"key":"4448_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00003246-200103000-00009","volume":"29","author":"E Azoulay","year":"2001","unstructured":"Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med. 2001;29:519\u201325.","journal-title":"Crit Care Med"},{"key":"4448_CR4","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/cc7713","volume":"13","author":"FS Taccone","year":"2009","unstructured":"Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13:R15.","journal-title":"Crit Care"},{"key":"4448_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCM.0b013e3181c0349e","volume":"38","author":"M Soares","year":"2010","unstructured":"Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, et al. Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multicenter study. Crit Care Med. 2010;38:9\u201315.","journal-title":"Crit Care Med"},{"key":"4448_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jcrc.2014.04.007","volume":"29","author":"E Kostakou","year":"2014","unstructured":"Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care. 2014;29:817\u201322.","journal-title":"J Crit Care"},{"key":"4448_CR7","doi-asserted-by":"publisher","first-page":"R291","DOI":"10.1186\/cc2893","volume":"8","author":"MD Williams","year":"2004","unstructured":"Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8:R291\u20138.","journal-title":"Crit Care"},{"key":"4448_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cmi.2016.11.003","volume":"23","author":"EJ Giamarellos-Bourboulis","year":"2017","unstructured":"Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsi C, Sinapidis D, et al. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017;23:104\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"4448_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.1998.16.2.761","volume":"16","author":"JS Groeger","year":"1998","unstructured":"Groeger JS, Lemeshow S, Price K, Nierman DM, White P Jr, Klar J, et al. Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol. 1998;16:761\u201370.","journal-title":"J Clin Oncol"},{"key":"4448_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1532\/IJH97.E0625","volume":"85","author":"C Ferra","year":"2007","unstructured":"Ferra C, Marcos P, Misis M, Morgades M, Bordej\u00e9 ML, Oriol A, et al. Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. Int J Hematol. 2007;85:195\u2013202.","journal-title":"Int J Hematol"},{"key":"4448_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/codi.14432","volume":"21","author":"SM Sims","year":"2019","unstructured":"Sims SM, Kao AM, Spaniolas K, Celio AC, Sippey M, Heniford BT, et al. Chronic immunosuppressant use in colorectal cancer patients worsens postoperative morbidity and mortality through septic complications in a propensity-matched analysis. Colorectal Dis. 2019;21:156\u201363.","journal-title":"Colorectal Dis"},{"key":"4448_CR12","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.21037\/jtd.2018.06.165","volume":"10","author":"CC Lai","year":"2018","unstructured":"Lai CC, Ho CH, Chen CM, Chiang SR, Chao CM, Liu WL, et al. Risk factors and mortality of adults with lung cancer admitted to the intensive care unit. J Thorac Dis. 2018;10:4118\u201326.","journal-title":"J Thorac Dis"},{"key":"4448_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.diagmicrobio.2017.04.006","volume":"88","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Zhang W, Li Z, Bai C, Li D, Zheng S, et al. Bacteremia due to AmpC \u03b2-lactamase producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes. Diagn Microbiol Infect Dis. 2017;88:247\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4448_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2018.03.022","volume":"71","author":"Beda Islas-Mu\u00f1oz","year":"2018","unstructured":"Islas-Mu\u00f1oz B, Volkow-Fern\u00e1ndez P, Ibanes-Guti\u00e9rrez C, Villamar-Ram\u00edrez A, Vilar-Compte D, Cornejo-Ju\u00e1rez P. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int J Infect Dis. 2018;17:59\u201364.","journal-title":"International Journal of Infectious Diseases"},{"issue":"3","key":"4448_CR15","doi-asserted-by":"publisher","first-page":"e013502","DOI":"10.1136\/bmjopen-2016-013502","volume":"7","author":"Gilbert Abou Dagher","year":"2017","unstructured":"Dagher GA, El Khuri C, Chehadeh AAH, Chami A, Bachir R, Zebian D, et al. Are patients with cancer with sepsis and bacteremia at a higher risk of mortality? A retrospective chart review of patients presenting to a tertiary care Centre in Lebanon. BMJ Open. 2017;7:e013502.","journal-title":"BMJ Open"},{"key":"4448_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canep.2018.05.001","volume":"55","author":"JX Moore","year":"2018","unstructured":"Moore JX, Akinyemiju T, Bartolucci A, Wang HE, Waterbor J, Griffin R. A prospective study of cancer survivors and risk of sepsis within the REGARDS cohort. Cancer Epidemiol. 2018;55:30\u20138.","journal-title":"Cancer Epidemiol"},{"issue":"Suppl","key":"4448_CR17","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ijantimicag.2015.10.011","volume":"46","author":"J Eugen-Olsen","year":"2015","unstructured":"Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: the unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents. 2015;46(Suppl):S33\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4448_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/liv.12705","volume":"35","author":"Athina Chounta","year":"2014","unstructured":"Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, et al. Serum soluble urokinase plasminogen activator receptor as a screening tool for the early diagnosis of hepatocellular carcinoma. Liver Int. 2015;35:601\u20137.","journal-title":"Liver International"},{"key":"4448_CR19","volume":"7","author":"S Vallabhajosyula","year":"2018","unstructured":"Vallabhajosyula S, Deshmukh AJ, Kashani K, Prasad A, Sakhuja A. Tako-Tsubo cardiomyopathy in severe sepsis: nationwide trends, predictors, and outcomes. J Am Heart Assoc. 2018;7:e009160.","journal-title":"J Am Heart Assoc"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4448-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4448-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4448-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T23:05:52Z","timestamp":1601939152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4448-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4448-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"13 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the following Ethics Committees:\u2022 Ethics Committee of ATTIKON University General Hospital of Athens\u2022 Ethics Committee of Asklipieion General Hospital of Voula, Territory of Athens\u2022 Ethics Committee of \u201cCenter for Trauma Resuscitation- KAT\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cEvangelismos\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cEvgenideio\u201d Hospital of Athens\u2022 Ethics committee of \u201cIppokrateion\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cG. Gennimatas\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cLaikon\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cKonstantopouleio-Aghia Olga\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cKorgialeneion-Benakion\u201d General Hospital of Athens\u2022 Ethics Committee of \u201cSotiria\u201d Athens General Hospital\u2022 Ethics Committee of \u201cThriasio\u201d Elefsis General Hospital\u2022 Ethics Committee of \u201cAghios Dimitrios\u201d General Hospital of Thessaloniki\u2022 Ethics Committee of \u201cG. Gennimatas\u201d General Hospital of Thessaloniki\u2022 Ethics Committee of \u201cAghios Pavlos\u201d General Hospital of Thessaloniki\u2022 Ethics Committee of \u201cTheagenio\u201d Hospital of Thessaloniki\u2022 Ethics Committee of \u201cTzaneio\u201d General Hospital of Piraeus\u2022 Ethics committee of University General Hospital of Alexandroupolis\u2022 Ethics Committee of University General Hospital of Ioannina\u2022 Ethics Committee of General Hospital of Korinthos\u2022 Ethics Committee of General Hospital of PtolemaidaThe patients were enrolled after written consent of themselves or their legal representative in the case of patients unable to consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"George Dimopoulos is an editorial board member for BMC Infectious Diseases.Evangelos J Giamarellos-Bourboulis has received honoraria (paid to the University of Athens) from AbbVie USA, Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, MSD Greece, Pfizer Greece and XBiotech Inc. He has received independent educational grants from AbbVie, Abbott, Astellas Pharma, AxisShield, bioM\u00e9rieux Inc., Inflammatix Inc., InflaRx GmbH, the Medicines Company and XBiotech Inc. He has received funding from the FrameWork 7 program HemoSpec and from the Horizon2020 Marie-Curie project European Sepsis Academy (granted to the National and Kapodistrian University of Athens).The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"831"}}